Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Gideon M. Hirschfield, DE Jones, John M. Vierling et al.|Journal of Hepatology|2018

Cited by 5